PTPRS is a novel marker for early tau pathology and synaptic integrity in Alzheimer’s disease

Abstract Background Synaptic dysfunction is a central pathologic feature of Alzheimer’s disease (AD), with synaptic loss even preceding neuronal loss in specific brain regions. In healthy individuals, synaptic function and plasticity are orchestrated through the complex integration of signaling inputs generated by cell surface receptors. Methods In this study, we investigate the role of one such receptor, protein tyrosine phosphatase receptor sigma (PTPRS), in the context of Alzheimer’s disease. Publicly available datasets (BRAINEAC, ROSMAP, ADC1) and a cohort of asymptomatic but “at risk” individuals (PREVENT‐AD) were used to explore the relationship between PTPRS and various Alzheimer’s disease biomarkers. Results We identified that PTPRS rs10415488 variant C shows features of neuroprotection against early phospho (181)‐tau pathology (p<0.005) and synaptic degeneration (GAP‐43, p<0.001) in Alzheimer’s disease. In brain tissues, PTPRS protein abundance was significantly correlated with the quantity of two markers of synaptic integrity: SNAP25(R 2 =0.20, p < 0.0001) and SYT‐1(R 2 =0.12, p < 0.0001). We also found the presence of sexual dimorphism for PTPRS, with higher CSF concentrations in males (p<0.001) than females. Male carriers for variant C exhibit a 10‐month delay in the onset of AD (p <0.05). One molecular function of PTPRS we chose to explore is macrophagy, given the implication of this biological process in the response against neurodegeneration. Macrophagy‐associated LC3 immunoreactivity occurs in most dystrophic neurites in AD and co‐localized with abnormal P‐tau in most neurofibrillary tangles. In the ROSMAP subjects, LC3 cortical protein levels were found to be significant reduced in C carriers Conclusions PTPRS acts as a soluble, secreted neuroprotective receptor, found in the extracellular space in Alzheimer’s disease. These findings also highlight the functional importance of synaptic plasticity in the protection against neurodegenerative diseases.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.086435
Primary Topic
Cancer-related cognitive impairment studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PTPRS is a novel marker for early tau pathology and synaptic integrity in Alzheimer’s disease

Isabelle Aubry, Michel L. Tremblay, Kaj Blennow, Judes Poirier et al.
Alzheimer s & Dementia
Cancer-related cognitive impairment studies
article

PTPRS is a novel marker for early tau pathology and synaptic integrity in Alzheimer’s disease

Isabelle Aubry, Michel L. Tremblay, Kaj Blennow, Judes Poirier, Anne Labonté, Cynthia Picard, Daniel Auld, Alexandre Poirier, Henrik Zetterberg
article en

Abstract

Abstract Background Synaptic dysfunction is a central pathologic feature of Alzheimer’s disease (AD), with synaptic loss even preceding neuronal loss in specific brain regions. In healthy individuals, synaptic function and plasticity are orchestrated through the complex integration of signaling inputs generated by cell surface receptors. Methods In this study, we investigate the role of one such receptor, protein tyrosine phosphatase receptor sigma (PTPRS), in the context of Alzheimer’s disease. Publicly available datasets (BRAINEAC, ROSMAP, ADC1) and a cohort of asymptomatic but “at risk” individuals (PREVENT‐AD) were used to explore the relationship between PTPRS and various Alzheimer’s disease biomarkers. Results We identified that PTPRS rs10415488 variant C shows features of neuroprotection against early phospho (181)‐tau pathology (p<0.005) and synaptic degeneration (GAP‐43, p<0.001) in Alzheimer’s disease. In brain tissues, PTPRS protein abundance was significantly correlated with the quantity of two markers of synaptic integrity: SNAP25(R 2 =0.20, p < 0.0001) and SYT‐1(R 2 =0.12, p < 0.0001). We also found the presence of sexual dimorphism for PTPRS, with higher CSF concentrations in males (p<0.001) than females. Male carriers for variant C exhibit a 10‐month delay in the onset of AD (p <0.05). One molecular function of PTPRS we chose to explore is macrophagy, given the implication of this biological process in the response against neurodegeneration. Macrophagy‐associated LC3 immunoreactivity occurs in most dystrophic neurites in AD and co‐localized with abnormal P‐tau in most neurofibrillary tangles. In the ROSMAP subjects, LC3 cortical protein levels were found to be significant reduced in C carriers Conclusions PTPRS acts as a soluble, secreted neuroprotective receptor, found in the extracellular space in Alzheimer’s disease. These findings also highlight the functional importance of synaptic plasticity in the protection against neurodegenerative diseases.

Alzheimer s & DementiaVol. 20(S2)
Douglas College (CA), Douglas Mental Health University Institute (CA), Sahlgrenska University Hospital (SE), Profu (Sweden) (SE), McGill University (CA), University of Gothenburg (SE)
Good health and well-being
Openalex Percentile: Top 56%
Cancer-related cognitive impairment studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.